Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
作者： Maddalena Sansovini , Stefano Severi , Alice Ambrosetti , Manuela Monti , Oriana Nanni
DOI: 10.1159/000348394
关键词:
摘要: Background: We evaluated the activity and safety profile of 177Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT) in patients with advanced G1
elsevier.com
karger.com
sci-hub.se 参考文章(24)
M Cremonesi, M Ferrari, A Di Dia, F Botta, C De Cicco, L Bodei, G Paganelli, Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging. ,vol. 55, pp. 155- 167 ,(2011)
J Norenberg, François Jamar, C Smith, WH Bakker, L Kvols, Stanislas Pauwels, B Stolz, EP Krenning, R Valkema, Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 28, pp. 1025- 1025 ,(2001)
C. Waldherr, M. Pless, H.R. Maecke, A. Haldemann, J. Mueller-Brand, The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology. ,vol. 12, pp. 941- 945 ,(2001) , 10.1023/A:1011160913619
Massimo Falconi, Detlef Klaus Bartsch, Barbro Eriksson, Günter Klöppel, José M. Lopes, Juan M. O'Connor, Ramón Salazar, Babs G. Taal, Marie Pierre Vullierme, Dermot O'Toole, ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors Neuroendocrinology. ,vol. 95, pp. 120- 134 ,(2012) , 10.1159/000335587
Nikiforos Ballian, Agnes G. Loeffler, Victoria Rajamanickam, Peter A. Norstedt, Sharon M. Weber, Clifford S. Cho, A simplified prognostic system for resected pancreatic neuroendocrine neoplasms Hpb. ,vol. 11, pp. 422- 428 ,(2009) , 10.1111/J.1477-2574.2009.00082.X
Sanjay Gupta, James C. Yao, Kamran Ahrar, Michael J. Wallace, Frank A. Morello, David C. Madoff, Ravi Murthy, Marshall E. Hicks, Jaffer A. Ajani, Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer Journal. ,vol. 9, pp. 261- 267 ,(2003) , 10.1097/00130404-200307000-00008
Ben Lawrence, Bjorn I. Gustafsson, Anthony Chan, Bernhard Svejda, Mark Kidd, Irvin M. Modlin, The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors Endocrinology and Metabolism Clinics of North America. ,vol. 40, pp. 1- 18 ,(2011) , 10.1016/J.ECL.2010.12.005
Phillip G. Claringbold, Paul A. Brayshaw, Richard A. Price, J. Harvey Turner, Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 38, pp. 302- 311 ,(2011) , 10.1007/S00259-010-1631-X
Christos Toumpanakis, Tim Meyer, Martyn E. Caplin, Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours Best Practice & Research Clinical Endocrinology & Metabolism. ,vol. 21, pp. 131- 144 ,(2007) , 10.1016/J.BEEM.2007.01.005
Stephanie Green, Geoffrey R. Weiss, Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs. ,vol. 10, pp. 239- 253 ,(1992) , 10.1007/BF00944177